What happens if I choose no treatment for CLL

Understanding "Watch and Wait" for CLL

This is an excellent question, and it's important to know that choosing no immediate treatment is actually a standard, evidence-based approach for many CLL patients—not a risky decision.

The Clinical Approach: "Watch and Wait"

According to the NCCN Guidelines for CLL, many patients with early-stage, asymptomatic chronic lymphocytic leukemia are managed with observation rather than immediate treatment. This approach is based on decades of clinical experience showing that:

• Not all CLL patients need immediate treatment — Some people's CLL grows very slowly and may never require therapy during their lifetime
• Early treatment doesn't improve survival — Research shows that treating asymptomatic CLL early doesn't help patients live longer than waiting until symptoms develop
• You avoid treatment side effects — By delaying therapy, you avoid potential complications from chemotherapy, targeted drugs, or other treatments while your disease is stable

What "Watch and Wait" Involves

During this monitoring period, you would typically have:

• Regular blood tests to monitor your white blood cell counts and other blood values
• Physical exams to check for enlarged lymph nodes or spleen
• Periodic imaging (CT scans) if symptoms suggest progression
• Discussion with your oncologist about any new symptoms

When Treatment Usually Becomes Necessary

According to NCCN Guidelines, treatment is typically started when CLL becomes active, meaning:

• Rapidly rising lymphocyte counts
• Enlarged lymph nodes, spleen, or liver causing symptoms
• Anemia (low red blood cells) or low platelet counts
• B-symptoms (fever, night sweats, weight loss)
• Infections becoming more frequent

Important Prognostic Factors

Your specific situation matters. NCCN Guidelines note that doctors consider several factors when deciding if observation is appropriate:

• Genetic markers (like IGHV mutation status, del(17p), TP53 mutations) — these help predict how aggressive your CLL might be
• Lactate dehydrogenase (LDH) levels — elevated levels may suggest more active disease
• Beta-2 microglobulin levels — higher levels can indicate faster progression
• Your age and overall health

Patients with favorable genetic markers and stable disease are better candidates for watch-and-wait.

Potential Risks of Observation

While watch-and-wait is safe for appropriate patients, there are considerations:

• Disease progression — Your CLL will eventually require treatment (though this may take years or decades)
• Monitoring burden — Regular appointments and tests are necessary
• Psychological impact — Living with an untreated cancer diagnosis can be emotionally challenging for some patients
• Rare transformation — According to NCCN Guidelines, about 2-10% of CLL patients experience Richter transformation (conversion to an aggressive lymphoma), though this is uncommon

Questions to Ask Your Oncologist

To determine if watch-and-wait is right for YOUR situation:

1. Based on my genetic testing and prognostic factors, is my CLL considered low-risk, intermediate-risk, or high-risk?
2. How often will I need monitoring appointments and blood tests?
3. What specific symptoms or lab changes would trigger starting treatment?
4. Are there any clinical trials available that might be appropriate for me?
5. How will we track my disease progression, and what's your timeline for reassessing this approach?

The Bottom Line

Choosing observation for CLL is not passive or risky—it's an active, evidence-based management strategy supported by NCCN Guidelines. Your oncologist will monitor you carefully and start treatment when your disease becomes active. Many CLL patients live for years or even decades with watch-and-wait as their primary approach.

According to NCCN Guidelines, the key is having regular communication with your healthcare team about your disease status and being alert to symptoms that might indicate progression.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.